Skip to content

    Brain & Nervous System Health Center

    Font Size

    Electroconvulsive Therapy Under New Scrutiny

    Advisory Panel Says FDA Should Not Ease Restrictions on Treatment for Severe Depression
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    Jan. 28, 2011 -- The recommendations of an FDA advisory panel could mean new restrictions on electroconvulsive therapy -- a controversial treatment used by tens of thousands of U.S. patients with severe depression and other mental disorders.

    The experts urged the FDA not to ease restrictions on electroconvulsive therapy (ECT) for many patients. The agency is reviewing the safety of the treatment and could now require companies to prove to the government that their products are safe.

    Electroconvulsive therapy involves the delivery of a series of electric shocks through the scalp to the brain. As many as 100,000 patients receive ECT each year in the U.S., mostly for severe depression or other disorders that do not respond to medications.

    ECT machines have escaped strict scrutiny by the FDA largely because they were already on the market when the agency tightened rules three decades ago. The treatment is widely viewed as effective for patients who have few other options. But concerns over long-term safety have prompted new attention from regulators.

    ECT Side Effects

    Of most concern to the FDA is the risk of cognitive side effects, like memory loss, especially after prolonged use of ECT. While most experts agree that the benefits of short-term ECT treatments outweigh the risks for severely depressed patients, few studies look at the effects past six months, experts said.

    Members of the advisory panel on Friday urged the FDA not to reclassify ECT machines as generally safe for patients with several disorders, including schizophrenia and schizophrenia-like disorders, bipolar mania, and catatonia -- a mental state in which patients sometimes are in a stupor.

    The panel split on whether the agency should ease restrictions on ECT for patients with severe depression. While ECT was viewed as largely effective, experts said they had little information on how to make it safer.

    “I think the data is lacking on how we can better mitigate the risks,” said Jane Paulsen, PhD, a neuropsychology researcher at the University of Iowa.

    If the FDA keeps its most restrictive “Class III” designation for ECT, companies would have to submit applications showing their machines are safe and effective. Those may be outdated or may not exist at all for many devices, prompting worries that some machines could be forced off the market.

    Today on WebMD

    nerve damage
    Learn how this disease affects the nervous system.
    senior woman with lost expression
    Know the early warning signs.
    woman in art gallery
    Tips to stay smart, sharp, and focused.
    medical marijuana plant
    What is it used for?
    woman embracing dog
    boy hits soccer ball with head
    red and white swirl
    marijuana plant
    brain illustration stroke
    nerve damage
    Alzheimers Overview
    Graphic of number filled head and dna double helix